Here’s how analysts see Lantheus Holdings, Inc. (NASDAQ:LNTH) after this past week.

March 13, 2018 - By Marie Mckinney

 Here's how analysts see Lantheus Holdings, Inc. (NASDAQ:LNTH) after this past week.

Lantheus Holdings, Inc. (NASDAQ:LNTH) Ratings Coverage

Among 6 analysts covering Lantheus Holdings (NASDAQ:LNTH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Lantheus Holdings had 16 analyst reports since August 31, 2015 according to SRatingsIntel. As per Tuesday, October 10, the company rating was maintained by Jefferies. The firm has “Buy” rating by Wells Fargo given on Thursday, November 2. Jefferies maintained it with “Buy” rating and $1800 target in Thursday, June 29 report. The company was maintained on Wednesday, August 2 by Credit Suisse. On Friday, November 3 the stock rating was maintained by Credit Suisse with “Neutral”. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, February 24 report. The stock of Lantheus Holdings, Inc. (NASDAQ:LNTH) has “Buy” rating given on Monday, July 17 by Cantor Fitzgerald. As per Friday, December 11, the company rating was downgraded by Credit Suisse. On Friday, September 23 the stock rating was initiated by Credit Suisse with “Neutral”. On Monday, August 29 the stock rating was maintained by Jefferies with “Buy”. Below is a list of Lantheus Holdings, Inc. (NASDAQ:LNTH) latest ratings and price target changes.

03/11/2017 Broker: Credit Suisse Rating: Neutral Old Target: $19 New Target: $23 Maintain
03/11/2017 Broker: Jefferies Rating: Buy New Target: $27.0 Maintain
02/11/2017 Broker: Wells Fargo Rating: Buy New Target: $26.0 Upgrade
10/10/2017 Broker: Jefferies Rating: Buy New Target: $22.0 Maintain

The stock decreased 2.08% or $0.35 during the last trading session, reaching $16.45. About 285,468 shares traded. Lantheus Holdings, Inc. (NASDAQ:LNTH) has risen 644.29% since March 13, 2017 and is uptrending. It has outperformed by 627.59% the S&P500.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company has market cap of $622.81 million. The Company’s principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow. It has a 5.19 P/E ratio. The firm also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke.

More notable recent Lantheus Holdings, Inc. (NASDAQ:LNTH) news were published by: which released: “Annual Credit Suisse Healthcare Conference” on October 24, 2017, also with their article: “Form 4 Lantheus Holdings, Inc. For: Mar 05 Filed by: Crowley John W.” published on March 07, 2018, published: “Lantheus Holdings to Host Fourth Quarter and Full Year 2017 Earnings …” on February 12, 2018. More interesting news about Lantheus Holdings, Inc. (NASDAQ:LNTH) were released by: and their article: “Lantheus Holdings, Inc. Reports 2017 Third Quarter Financial Results; Exceeds …” published on November 02, 2017 as well as‘s news article titled: “Lantheus Presents New Data on Novel Cardiac PET Imaging Agent LMI 1195 in …” with publication date: March 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: